The FDA approved Moderna’s mFlusiva in August 2026, the first mRNA-based seasonal flu vaccine, for adults 50 and older, based on a Phase 3 trial of more than 4…
An H1N1 virus killed an estimated 50 million people worldwide -- the historical baseline behind every flu vaccine effort since.
Egg-based manufacturing, developed with US Army-funded research, becomes the founding platform for flu vaccination.
Modified-nucleoside chemistry solves mRNA’s inflammation problem -- later recognized with the 2023 Nobel Prize.
Built on mRNA research, years before any mRNA vaccine had ever been licensed anywhere in the world.
Flucelvax and Flublok diversify flu vaccine manufacturing beyond eggs for the first time in 70 years.
The FDA authorizes Moderna’s COVID-19 vaccine, generating years of real-world mRNA safety data.
Moderna launches its pivotal trial for mRNA-1010 in adults 50 and older across multiple countries.
The first mRNA seasonal flu vaccine is licensed for adults 50 and older -- traditional and accelerated approval.
Read the complete story, FAQs and key facts.